World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
76
Citations
16452
World Ranking
18934
National Ranking
9436

Richard G. Stock publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Richard G. Stock sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 440 publications — 47th percentile

47% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Richard G. Stock D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Richard G. Stock sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 76 D-Index — 8th percentile

8% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Richard G. Stock is affiliated with the Icahn School of Medicine at Mount Sinai in the United States. Their research primarily focuses on medical fields related to cancer treatment, particularly prostate cancer, with extensive work in radiation therapy and oncology.

The research output of Richard G. Stock covers several main fields and subfields of study:

  • Medicine
  • Pulmonary and Respiratory Medicine
  • Radiation
  • Oncology
  • Cancer Research
  • Radiology, Nuclear Medicine and Imaging

Their work incorporates a broad range of topics centered on cancer and radiotherapy, including:

  • Prostate Cancer Treatment and Research
  • Prostate Cancer Diagnosis and Treatment
  • Advanced Radiotherapy Techniques
  • Bladder and Urothelial Cancer Treatments
  • Radiopharmaceutical Chemistry and Applications
  • Cancer, Lipids, and Metabolism
  • Effects of Radiation Exposure

Several frequent publication venues have featured their work, highlighting consistent contributions to peer-reviewed journals important in the oncology and radiation therapy communities:

  • Brachytherapy
  • International Journal of Radiation Oncology*Biology*Physics
  • Radiotherapy and Oncology
  • Journal of Clinical Oncology
  • The Journal of Urology

Recent papers authored or co-authored by Richard G. Stock include:

  • "A biochemical definition of cure after brachytherapy for prostate cancer," 2020, Radiotherapy and Oncology
  • "Low dose rate brachytherapy for primary treatment of localized prostate cancer: A systemic review and executive summary of an evidence-based consensus statement," 2021, Brachytherapy
  • "Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer," 2022, JAMA Oncology
  • "Development of a method for generating SNP interaction-aware polygenic risk scores for radiotherapy toxicity," 2021, Radiotherapy and Oncology
  • "A Deep Learning Approach Validates Genetic Risk Factors for Late Toxicity After Prostate Cancer Radiotherapy in a REQUITE Multi-National Cohort," 2020, Frontiers in Oncology

Collaborations are a key component of their research, with frequent co-authors including:

  • Gregory S. Merrick
  • Brian J. Moran
  • Eric M. Horwitz
  • Barry S. Rosenstein
  • J.K. Wong

Best Publications

  • A dose-response study for I-125 prostate implants

    R G Stock;N N Stone;A Tabert;C Iannuzzi

  • Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group.

    Peter Grimm;Ignace Billiet;David Bostwick;Adam P Dicker

  • The american brachytherapy society recommendations for permanent prostate brachytherapy postimplant dosimetric analysis

    Subir Nag;William Bice;Keith DeWyngaert;Bradley Prestidge

  • American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy

    Brian J. Davis;Eric M. Horwitz;W. Robert Lee;Juanita M. Crook

  • IDENTIFICATION OF PATIENTS AT INCREASED RISK FOR PROLONGED URINARY RETENTION FOLLOWING RADIOACTIVE SEED IMPLANTATION OF THE PROSTATE

    Mitchell D. Terk;Richard G. Stock;Nelson N. Stone

  • A modified technique allowing interactive ultrasound-guided three-dimensional transperineal prostate implantation

    Richard G. Stock;Nelson N. Stone;Michael F. Wesson;J.Keith DeWyngaert

  • Biologically effective dose values for prostate brachytherapy: effects on PSA failure and posttreatment biopsy results.

    Richard G. Stock;Nelson N. Stone;Jamie A. Cesaretti;Barry S. Rosenstein

  • Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer.

    Amar U. Kishan;Ryan R. Cook;Jay P. Ciezki;Ashley E. Ross

  • Defining the risk of developing grade 2 proctitis following 125I prostate brachytherapy using a rectal dose-volume histogram analysis.

    Kurt M Snyder;Richard G Stock;Suzanne M Hong;Yeh Chi Lo

  • Intraoperative planning and evaluation of permanent prostate brachytherapy: report of the American Brachytherapy Society.

    Subir Nag;Jay P Ciezki;Robert Cormack;Stephen Doggett

  • LAPAROSCOPIC PELVIC LYMPH NODE DISSECTION FOR PROSTATE CANCER: COMPARISON OF THE EXTENDED AND MODIFIED TECHNIQUES

    Nelson N. Stone;Richard G. Stock;Pamela Unger

  • PENILE ERECTILE FUNCTION AFTER PERMANENT RADIOACTIVE SEED IMPLANTATION FOR TREATMENT OF PROSTATE CANCER

    Richard G. Stock;Johnny Kao;Nelson N. Stone

  • Complications following permanent prostate brachytherapy

    N.N. Stone;R.G. Stock

  • Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: Importance of patient selection and implant quality

    Marisa A Kollmeier;Richard G Stock;Nelson Stone

  • Genome-wide association study to identify single nucleotide polymorphisms (SNPs) associated with the development of erectile dysfunction in African-American men after radiotherapy for prostate cancer.

    Sarah L. Kerns;Harry Ostrer;Richard Stock;William Li

  • Long-Term Outcome and Toxicity of Salvage Brachytherapy for Local Failure After Initial Radiotherapy for Prostate Cancer

    Ryan J. Burri;Nelson N. Stone;Pam Unger;Richard G. Stock

  • Role of hormonal therapy in the management of intermediate- to high-risk prostate cancer treated with permanent radioactive seed implantation.

    Lucille N Lee;Richard G Stock;Nelson N Stone

  • Multicenter Analysis of Effect of High Biologic Effective Dose on Biochemical Failure and Survival Outcomes in Patients With Gleason Score 7–10 Prostate Cancer Treated With Permanent Prostate Brachytherapy

    Nelson N. Stone;Louis Potters;Brian J. Davis;Jay P. Ciezki

  • A 30-Year Experience in the Management of Primary Carcinoma of the Vagina: Analysis of Prognostic Factors and Treatment Modalities

    Richard G. Stock;Alex S.J. Chen;Jan Seski

  • Prostate-specific antigen bounce after prostate seed implantation for localized prostate cancer: descriptions and implications.

    Richard G Stock;Nelson N Stone;Jamie A Cesaretti

Frequent Co-Authors

Michael J. Zelefsky
Michael J. Zelefsky Memorial Sloan Kettering Cancer Center
Eric M. Horwitz
Eric M. Horwitz Fox Chase Cancer Center
Harry Ostrer
Harry Ostrer Albert Einstein College of Medicine
William Oh
William Oh Icahn School of Medicine at Mount Sinai
Phuoc T. Tran
Phuoc T. Tran Johns Hopkins University School of Medicine
Dirk De Ruysscher
Dirk De Ruysscher Maastricht University
Michael W. Kattan
Michael W. Kattan Cleveland Clinic
Mack Roach
Mack Roach University of California, San Francisco
Daniel E. Spratt
Daniel E. Spratt University of Michigan–Ann Arbor
Patrick A. Kupelian
Patrick A. Kupelian University of California, Los Angeles

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in Medicine doesn’t always mean following the classic path of becoming a physician. Today, a range of online health degrees open diverse pathways—for both clinical and non-clinical roles—offering flexibility and accessibility.

For those interested in leadership or administrative roles, pursuing a health care administration online degree provides a strong foundation. These programs are designed to equip students with management skills for hospitals, clinics, and public health organizations.

If you’re seeking advanced leadership positions, the cheapest mha programs (Master of Healthcare Administration) offer affordable routes to obtaining in-depth expertise in healthcare systems and policy.

For nurses aiming to reach the highest clinical practice levels, consider the cheapest dnp programs (Doctor of Nursing Practice). These flexible online options help advance careers without sacrificing current commitments.

Finally, pharmacists can benefit from modern online pharmacy school programs, streamlining the route to a doctorate and expanding options in research, clinical practice, or pharmaceutical administration.

Best Scientists Citing Richard G. Stock

Trending Scientists

Recently Published Articles